TSTickerStarGet alerts

MapLight Reports Q3 2026 Net Loss of $51.6M, Advances ZEPHYR-2 Phase 3 Trial Planning

MapLight Therapeutics reported Q3 2026 net loss of $51.6 million versus $29.4 million in Q3 2025, with R&D expenses increasing to $44.2 million from $27.1 million year-over-year due to clinical trial advancement and increased employee-related costs including stock-based compensation. The company ended Q3 2026 with $463.4 million in cash, cash equivalents and investments, expected to fund operations through 2028. The company initiated start-up activities for ZEPHYR-2, its planned Phase 3 trial of ML-007C-MA in sc...

Share this story

Key takeaways

  • Net loss widened to $51.6 million in Q3 2026 from $29.4 million in Q3 2025, driven by increased R&D and G&A spending

  • R&D expenses increased 63% year-over-year to $44.2 million due to clinical trial advancement and higher stock-based compensation ($5.8 million increase)

  • Cash position of $463.4 million as of September 30, 2026 expected to fund operations through 2028

  • ZEPHYR-2 Phase 3 trial initiation underway for ML-007C-MA in schizophrenia with topline results expected in 2H 2027

  • Phase 2 VISTA trial in Alzheimer's disease psychosis enrollment ongoing with topline results expected in 2028

  • ML-007C-MA received FDA Fast Track designation in December 2025 for ADP treatment

  • Company completed $150 million private placement in August 2026 to support clinical development

Key metrics

Net lossQ3 2026
$51.6 million$22.2 million increase in net loss
Net loss per share (basic and diluted)Q3 2026
-$0.97$36.21 improvement from -$37.18
Net lossNine months 2026
$172.5 million$90.9 million increase in net loss
Net loss per share (basic and diluted)Nine months 2026
-$3.60$102.10 improvement from -$105.70
Cash, cash equivalents and investmentsSeptember 30, 2026
$463.4 million
R&D expensesQ3 2026
$44.2 million$17.1 million increase (63%)
R&D expensesNine months 2026
$151.3 million$77.6 million increase (105%)
G&A expensesQ3 2026
$11.1 million$6.7 million increase (152%)

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow MPLT in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert